Generalized data of criteria of risk factors for the use of the drug torasemide from the materials of its preclinical studies

This study presents the review and analysis of materials, the summary of the data on the results of experimental (preclinical) pharmacological studies of the drug Torasemide and the results of clinical studies of the original drug Demadex, based on risk factors influencing the outcomes of hypertension in people. The information on the efficacy and safety of the drugs based on Torasemide is also presented in the relevant sections of the article. The search for information sources for the review was carried out using domestic and international databases elibrary and PubMed, applying contextual queries, including international non-proprietary names, terms of preclinical studies of pharmacokinetics, pharmacodynamics, and animal species used. This review considers the aspects of safety, pharmacokinetics, primary and secondary pharmacodynamics of Torasemide, available in various sources describing its preclinical studies. The summarized data presented in the study, in our opinion, may be used by researchers who are engaged in preclinical and clinical studies, as well as the issues of studying the efficacy and safety of generic drugs used in the treatment of patients with arterial hypertension and other cardiovascular pathology. The information on the advantages of Torasemide in comparison with Furosemide in the treatment of animals with simulated arterial hypertension deserves special consideration.